Drug Pipeline

KAI-9531 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
3
Recruiting
3
Phase 3
1
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-09 NCT07284901
Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With…
Trial sites expanded: 49 -> 52 locations
2026-05-30 NCT07458269
Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants…
overall status: "Recruiting" → "Enrolling By Invitation"
Active Studies by Phase
Phase 3
3
Phase 2
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT07284875 Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With… Obesity Recruiting
NCT07284901 Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With… Obesity With Diabetes Recruiting
NCT07284979 Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and… Obesity Recruiting
Phase 2
NCT07458269 Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants… Obesity Enrolling by Invitation
Sponsors Running KAI-9531 Trials
Disease Areas
Get alerts when KAI-9531 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free